Elevance Health Aktie News

Electronic Arts' shares outperformed the broader market during the period, driven by renewed investor confidence and momentum surrounding several high-profile product announcements. eBay's shares surged after reporting a strong second-quarter earnings report, bolstering confidence in the company's position in the marketplace. Elevance Health was the top underperformer over the period. Much of t...

Alphabet shares rose 38% during the quarter, which represents a striking $810 billion increase in market value. Samsung shares rose 36% in the quarter, adding over $100 billion of market value. Elevance's share price declined by 16%, making it our largest negative contributor.

Elevance Health reaffirmed its long-term goal of targeting at least 12% average annual growth in adjusted diluted EPS. ELV trades at a forward P/E of 11.5, below UNH's at 22, suggesting undervaluation if growth continues from 2026. The key risk remains a health benefit ratio above 90%, which will be closely monitored in upcoming quarters.

Annual premiums for U.S. families with employer-sponsored health insurance in 2025 rose 6% to nearly $27,000, reflecting higher spending on popular weight-loss treatments and other prescription drugs, according to a survey by health-policy organization KFF.

MINNEAPOLIS--(BUSINESS WIRE)-- #HistoSonics--HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 45.4 Million Elevance Health Members.

Elevance Health reported Q3 results, beating consensus earnings estimates. However, the beat was due to one-off items. Key focus areas include Medical Cost Ratio stabilization, 2026 premium rate re-filings, updates on Medicare segment growth, and membership trends for ELV. The benefit expense ratio continues to be elevated; the outlook for 2026 is for further deterioration in Medicaid results; ...

Elevance Health, Inc. (NYSE:ELV ) Q3 2025 Earnings Call October 21, 2025 8:30 AM EDT Company Participants Nathan Rich - Vice President of Investor Relations Gail Boudreaux - President, CEO & Director Mark Kaye - Executive VP & CFO Felicia Norwood - Executive VP & President of Government Health Benefits Peter Haytaian - Executive VP and President of Carelon & CarelonRx Conference Call Participan...

Elevance Health Tuesday said third quarter net income rose to nearly $1.2 billion despite rising costs in its government subsidized health insurance plans.